The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice
Open accessAbstract
BACKGROUND: The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton's tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. However, the potential regulation of neuroinflammatory responses in the brain by ibrutinib has not been comprehensively examined. METHODS: BV2 microglial cells were treated with ibrutinib (1 μM) or vehicle (1% DMSO), followed by lipopolysaccharide (LPS; 1 μg/ml) or PBS. RT-PCR, immunocytochemistry, and subcellular fractionation were performed to examine the effects of ibrutinib on neuroinflammatory responses. In addition, wild-type mice were sequentially injected with ibrutinib (10 mg/kg, i.p.) or vehicle (10% DMSO, i.p.), followed by LPS (10 mg/kg, i.p.) or PBS, and microglial and astrocyte activations were assessed using immunohistochemistry. RESULTS: Ibrutinib significantly reduced LPS-induced increases in proinflammatory cytokine levels in BV2 microglial and primary microglial cells but not in primary astrocytes. Ibrutinib regulated TLR4 signaling to alter LPS-induced proinflammatory cytokine levels. In addition, ibrutinib significantly decreased LPS-induced increases in p-AKT and p-STAT3 levels, suggesting that ibrutinib attenuates LPS-induced neuroinflammatory responses by inhibiting AKT/STAT3 signaling pathways. Interestingly, ibrutinib also reduced LPS-induced BV2 microglial cell migration by inhibiting AKT signaling. Moreover, ibrutinib-injected wild-type mice exhibited significantly reduced microglial/astrocyte activation and COX-2 and IL-1β proinflammatory cytokine levels. CONCLUSIONS: Our data provide insights on the mechanisms of a potential therapeutic strategy for neuroinflammation-related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhang, F., & Xu, R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.132 · Cited by 93
RetractedMD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4
Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K., Miyake, K., & Kimoto, M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1777 · Cited by 2,185
Debris clearance by microglia: an essential link between degeneration and regeneration
Neumann, H., Kotter, M. R., & Franklin, R. J. M. (2008) · Brain · doi:10.1093/brain/awn109 · Cited by 1,111
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Systemic inflammation and microglial activation: systematic review of animal experiments
Hoogland, I. C. M., Houbolt, C., van Westerloo, D. J., van Gool, W. A., & van de Beek, D. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0332-6 · Cited by 957
Toll-Like Receptors in Antiviral Innate Immunity
Lester, S. N., & Li, K. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.11.024 · Cited by 735
Park, J., Min, J.-S., Kim, B., Chae, U.-B., Yun, J. W., Choi, M.-S., Kong, I.-K., Chang, K.-T., & Lee, D.-S. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.016 · Cited by 529
Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential
Hanke, M. L., & Kielian, T. (2011) · Clinical Science · doi:10.1042/cs20110164 · Cited by 492
Yokogami, K., Wakisaka, S., Avruch, J., & Reeves, S. A. (2000) · Current Biology · doi:10.1016/s0960-9822(99)00268-7 · Cited by 469
Role of microglia in CNS inflammation
Graeber, M. B., Li, W., & Rodriguez, M. L. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.033 · Cited by 392
Cited by
Li, W., Ali, T., He, K., Liu, Z., Shah, F. A., Ren, Q., Liu, Y., Jiang, A., & Li, S. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.008 · Cited by 263
Bruton’s tyrosine kinase inhibition in multiple sclerosis
Schneider, R., & Oh, J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01229-z · Cited by 47
Kim, J., Kim, S.-J., Jeong, H.-R., Park, J.-H., Moon, M., & Hoe, H.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903309 · Cited by 23
Self-citationTmem119 expression is downregulated in a subset of brain metastasis-associated microglia
Ma, W., Oswald, J., Rios Angulo, A., & Chen, Q. (2024) · BMC Neuroscience · doi:10.1186/s12868-024-00846-3 · Cited by 15
Li, S., Lu, C., Zhao, Z., Lu, D., & Zheng, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1161405 · Cited by 12
Metadata
- Authors
- Nam, H. Y., Nam, J. H., Yoon, G., Lee, J.-Y., Nam, Y., Kang, H.-J., Cho, H.-J., Kim, J., & Hoe, H.-S.
- Venue
- Journal of Neuroinflammation
- Published
- 2018-09-19
- Volume
- 15
- Issue
- 1
- Pages
- 271-271
- ISSN
- 1742-2094 (ISSN-L)
- OpenAlex
- W2891163459
- Cited by
- 261
- References
- 54
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice. https://app.cochat.ai/papers/10.1186/s12974-018-1308-0
- The paper
- Nam, H. Y., Nam, J. H., Yoon, G., Lee, J.-Y., Nam, Y., Kang, H.-J., Cho, H.-J., Kim, J., & Hoe, H.-S. (2018). Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-018-1308-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.